Roche Co-Developed Drugs Deliver Early Synergistic Results Without Added Toxicities
This article was originally published in The Pink Sheet Daily
One + one turned into a possible three when Genentech drugs targeting PI3K and MEK were combined in an early solid tumor study reported at the American Association for Cancer Research meeting April 2.
You may also be interested in...
Partnering its PD-1-specific antibody candidate with three other companies, Merck indicates a new era may have arrived for testing novel agents in combination. Also, NIH partners with 10 biopharmas to transform the discovery model and Myriad moves to buy Crescendo.
Right Dosing, Scheduling Key To Anticipating Resistance, Creating Synergistic Combos In Drug Development
The art of developing synergistic combinations of novel drugs that can win the race against resistance mutations was much discussed at the American Association for Cancer Research meeting in Chicago March 31 - April 4.
FDA put together its well-received draft guidance on co-development of experimental drugs to be used in combination in less than a year, but even with regulators on board and the science burgeoning, the timeline for finding predictable ways for companies to actually collaborate on combining investigative cancer therapies looks to be much longer.